Cellular Biomedicine Group (CBMG) Announces Completion of Wuxi GMP Facility Expansion
30 March 2017 - 11:49PM
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the
“Company”), a leading clinical-stage biopharmaceutical firm engaged
in the development of effective immunotherapies for cancer and stem
cell therapies for degenerative diseases, today announced the
completion of its newly expanded 30,000 square foot facility in
Huishan High Tech Park in Wuxi, China. 20,000 square feet of the
Wuxi GMP facility will be dedicated to advanced stem cell
culturing, centralized plasmid and viral vector production, cell
banking and development of reagents. By the end of 2017, the
Company anticipates that the combination of this Wuxi site, the new
Zhangjiang Shanghai and the Beijing GMP facilities will be capable
of supporting simultaneous clinical trials for five different
CAR-T and stem cell products, or capacity to treat up to 10,000
cancer and 10,000 Knee Osteoarthritis (KOA) patients per year.
A photo accompanying this announcement is available
at http://www.globenewswire.com/NewsRoom/AttachmentNg/5e253f76-4330-47de-bae1-a47fd6aaff31
“As we have previously stated, this marks a key milestone in our
corporate development in the first quarter of 2017 as we continue
to invest in and expand our capabilities in advanced CAR-T and stem
cell manufacturing. We have long recognized the logistical
challenges of delivering consistent, quality and clinical grade
processes to deliver cell therapies to market and we have
differentiated our capabilities to meet this challenge. We will now
be able to centralize, standardize and automate our manufacturing
capabilities fully in-house while enhancing our capacity to
meet the production demands of multiple products in development as
part of our overall Chemistry, Manufacturing, and Controls (“CMC”)
process,” said Tony (Bizuo) Liu, Chief Executive Officer of
Cellular Biomedicine Group.
“The Wuxi facility is equipped with six independent production
lines and will be capable of producing and banking low
endotoxin high transfection rate plasmids, and high titer automated
and purified virus with stringent quality control,” commented Helen
Zhang, SVP of Technology & Manufacturing for CBMG.
CBMG recently commenced two Phase I human
clinical trials in China using CAR-T to treat relapsed/refractory
CD19+ B-cell Acute Lymphoblastic Leukemia (ALL) and Refractory
Diffuse Large B-cell Lymphoma (DLBCL) as well as an ongoing Phase I
trial in China for AlloJoinTM (CBMG’s “Off-the-Shelf” Allogeneic
Human Adipose-derived Mesenchymal Stem Cell) for the treatment of
Knee Osteoarthritis (KOA). CBMG was also recently awarded $2.29
million from the California Institute for Regenerative Medicine
(CIRM) to support pre-clinical studies of AlloJoinTM for Knee
Osteoarthritis in the United States.
About Cellular Biomedicine Group Cellular
Biomedicine Group, Inc. develops proprietary cell therapies for the
treatment of cancer and degenerative diseases. We conduct
immuno-oncology and stem cell clinical trials in China using
products from our integrated GMP laboratory. Our GMP facilities in
China, consisting of twelve independent cell production lines, are
designed and managed according to both China and U.S. GMP
standards. CBMG recently commenced two Phase I human clinical
trials in China using CAR-T to treat relapsed/refractory CD19+
B-cell Acute Lymphoblastic Leukemia (ALL) and Refractory Diffuse
Large B-cell Lymphoma (DLBCL) as well as an ongoing Phase I trial
in China for AlloJoinTM (CBMG’s “Off-the-Shelf” Allogeneic Human
Adipose-derived Mesenchymal Stem Cell) for the treatment of Knee
Osteoarthritis (KOA). CBMG was also recently awarded $2.29 million
from the California Institute for Regenerative Medicine (CIRM) to
support pre-clinical studies of AlloJoinTM for Knee Osteoarthritis
in the United States. To learn more about CBMG, please visit
www.cellbiomedgroup.com.
Forward-looking Statements This press release
contains forward-looking statements—including descriptions of
plans, strategies, trends, specific activities, investments and
other non-historical facts—as defined by the Private Securities
Litigation Reform Act of 1995, Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. Forward-looking information is inherently
uncertain, and actual results could differ materially from those
anticipated due to a number of factors, which include risks
inherent in doing business, trends affecting the global economy
(including the devaluation of the RMB by China in August 2015), and
other risks detailed in CBMG’s reports filed with the Securities
and Exchange Commission, quarterly reports on form 10-Q, current
reports on form 8-K and annual reports on form 10-K.
Forward-looking statements may be identified by terms such as
"may," "will," "expects," "plans," "intends," "estimates,"
"potential," "continue" or similar terms or their negations.
Although CBMG believes the expectations reflected in the
forward-looking statements are reasonable, they cannot guarantee
that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
The photo is also available at Newscom, www.newscom.com, and via
AP PhotoExpress.
Contacts:
Sarah Kelly
Director of Corporate Communications, CBMG
+1 408-973-7884
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Citigate Dewe Rogerson
+1 347 481-3711
vivian.chen@citigatedr.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Apr 2024 to May 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From May 2023 to May 2024